Park, Wungki

Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer

Rojas, L. A., Sethna, Z., Soares, K. C., Olcese, C., Pang, N., Patterson, E., Lihm, J., Ceglia, N., Guasp, P., Chu, A., et al. (2023) · Nature

Immunotherapy and Immune ResponsesCancer Immunotherapy and Biomarkers

Cited by 1,432

Automated Real-World Data Integration Improves Cancer Outcome Prediction

Jee, J., Fong, C., Pichotta, K., Tran, T. N., Luthra, A., Waters, M., Fu, C., Altoe, M., Liu, S.-Y., Maron, S. B., et al. (2024) · Nature

Machine Learning in HealthcareCancer Genomics and Diagnostics

Cited by 188

Cost-effectiveness of Osimertinib in the First-Line Treatment of Patients With EGFR-Mutated Advanced Non–Small Cell Lung Cancer

Aguiar, P. N., Haaland, B., Park, W., San Tan, P., del Giglio, A., & de Lima Lopes, G. (2018) · JAMA Oncology

Health Systems, Economic Evaluations, Quality of LifeLung Cancer Treatments and Mutations

Cited by 124

Daraxonrasib in Previously Treated Advanced RAS -Mutated Pancreatic Cancer

Wolpin, B. M., Park, W., Garrido-Laguna, I., Spira, A., Starodub, A., Sommerhalder, D., Punekar, S. R., Barve, M., Pelster, M., Herzberg, B., et al. (2026) · New England Journal of Medicine

Pancreatic and Hepatic Oncology ResearchProtein Kinase Regulation and GTPase Signaling

Cited by 90

Erratum to: Antiangiogenic effects of ganetespib in colorectal cancer mediated through inhibition of HIF-1α and STAT-3

Nagaraju, G. P., Park, W., Wen, J., Mahaseth, H., Landry, J., Farris, A. B., Willingham, F., Sullivan, P. S., Proia, D. A., El-Hariry, I., et al. (2013) · Angiogenesis

Angiogenesis and VEGF in CancerCancer, Hypoxia, and Metabolism

Cited by 49

608O Preliminary safety and clinical activity of ASP3082, a first-in-class, KRAS G12D selective protein degrader in adults with advanced pancreatic (PC), colorectal (CRC), and non-small cell lung cancer (NSCLC)

Park, W., Kasi, A., Spira, A. I., Berlin, J. D., Wang, J. S., Herzberg, B., Kuboki, Y., Kitano, S., Pelster, M., Goldman, J. W., et al. (2024) · Annals of Oncology

Protein Degradation and InhibitorsPancreatic and Hepatic Oncology Research

Cited by 46

Pancreas cancer and BRCA : A critical subset of patients with improving therapeutic outcomes

Momtaz, P., O’Connor, C. A., Chou, J. F., Capanu, M., Park, W., Bandlamudi, C., Berger, M. F., Kelsen, D. P., Suehnholz, S. P., Chakravarty, D., et al. (2021) · Cancer

Pancreatic and Hepatic Oncology ResearchBRCA gene mutations in cancer

Cited by 44

Targeting DNA damage repair pathways in pancreas cancer

Crowley, F., Park, W., & O’Reilly, E. M. (2021) · Cancer and Metastasis Reviews

Pancreatic and Hepatic Oncology ResearchPARP inhibition in cancer therapy

Cited by 43

Clinico-genomic Characterization of ATM and HRD in Pancreas Cancer: Application for Practice

Park, W., O'Connor, C. A., Bandlamudi, C., Forman, D., Chou, J. F., Umeda, S., Reyngold, M., Varghese, A. M., Keane, F., Balogun, F., et al. (2022) · Clinical Cancer Research

Pancreatic and Hepatic Oncology ResearchBRCA gene mutations in cancer

Cited by 34

Trial in progress: A phase 1, first-in-human, open-label, multicenter, dose-escalation and dose-expansion study of ASP3082 in patients with previously treated advanced solid tumors and KRAS G12D mutations.

Tolcher, A. W., Park, W., Wang, J. S., Spira, A. I., Janne, P. A., Lee, H.-J., Gill, S., LoRusso, P., Herzberg, B., Goldman, J. W., et al. (2023) · Journal of Clinical Oncology

Protein Degradation and InhibitorsPancreatic and Hepatic Oncology Research

Cited by 33